Patents by Inventor Michael H. Nantz
Michael H. Nantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210071273Abstract: The presently disclosed subject matter relates to processes for isolating xylose from an aqueous solution. A representative process can comprise providing an aqueous solution comprising xylose; combining a boron compound with the aqueous solution to form a boron derivative of the xylose; isolating the boron derivative of the xylose from the aqueous solution as a precipitate; dissolving the boron derivative of the xylose in a solvent; and isolating the xylose from the solvent as a precipitate using a boron capture agent.Type: ApplicationFiled: December 11, 2018Publication date: March 11, 2021Inventors: Christopher T. Burns, Jagannadh Satyavolu, Michael H. Nantz
-
Patent number: 10407453Abstract: Provided are processes for isolating hemicellulose-based sugar from a biomass. The process includes providing a biomass hydrolyzate including a C5 sugar, forming a boronic ester or diester of the C5 sugar, extracting the boronic ester of diester of the C5 sugar, precipitating the C5 sugar using a boron capture agent, and isolating the C5 sugar from the precipitate. The isolated C5 sugar is provided in dry form.Type: GrantFiled: April 7, 2016Date of Patent: September 10, 2019Assignee: University of Louisville Research Foundation, Inc.Inventors: Jagannadh Satyavolu, Sadakatali S. Gori, Michael H. Nantz, Mandapati V. Ramakrishnam Raju, Christopher T. Burns
-
Patent number: 10342870Abstract: The invention provides therapeutic magnetic nanoparticles containing a therapeutic agent connected to a magnetic nanoparticle core through a stable functional group and a linker that can be induced to release the therapeutic agent from the core, through hydrolysis of the functional group. Also provided are methods for making nanoparticles, and methods for using nanoparticles.Type: GrantFiled: August 6, 2015Date of Patent: July 9, 2019Assignee: University of Louisville Research Foundation, Inc.Inventors: Michael H. Nantz, Ralph Knipp
-
Publication number: 20180185512Abstract: The invention provides nanoparticles, methods for making nanoparticles, and methods for using nanoparticles.Type: ApplicationFiled: November 3, 2017Publication date: July 5, 2018Applicant: University of Louisville Research Foundation, Inc.Inventors: Ralph J. Knipp, Michael H. Nantz
-
Patent number: 9849193Abstract: The invention provides nanoparticles, methods for making nanoparticles, and methods for using nanoparticles. An important attribute of a drug delivery system is its ability to allow for spatial and temporal regulated drug release, thereby minimizing side effects and improving therapeutic efficacy of conventional pharmaceuticals. Iron oxide nanoparticles (NPs), specifically Fe304 nanoparticles, possess many appropriate qualities that make them a viable choice for drug delivery.Type: GrantFiled: February 7, 2014Date of Patent: December 26, 2017Assignee: University of Louisville Research Foundation, Inc.Inventors: Ralph J. Knipp, Michael H. Nantz
-
Publication number: 20170224839Abstract: The invention provides therapeutic magnetic nanoparticles containing a therapeutic agent connected to a magnetic nanoparticle core through a stable functional group and a linker that can be induced to release the therapeutic agent from the core, through hydrolysis of the functional group. Also provided are methods for making nanoparticles, and methods for using nanoparticles.Type: ApplicationFiled: August 6, 2015Publication date: August 10, 2017Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Michael H. Nantz, Ralph Knipp
-
Publication number: 20160297845Abstract: Provided are processes for isolating hemicellulose-based sugar from a biomass. The process includes providing a biomass hydrolyzate including a C5 sugar, forming a boronic ester or diester of the C5 sugar, extracting the boronic ester of diester of the C5 sugar, precipitating the C5 sugar using a boron capture agent, and isolating the C5 sugar from the precipitate. The isolated C5 sugar is provided in dry form.Type: ApplicationFiled: April 7, 2016Publication date: October 13, 2016Inventors: Jagannadh SATYAVOLU, Sadakatali S. GORI, Michael H. Nantz, Ramakrishnam Raju MANDAPATI, Christopher T. BURNS
-
Publication number: 20150374849Abstract: The invention provides nanoparticles, methods for making nanoparticles, and methods for using nanoparticles. An important attribute of a drug delivery system is its ability to allow for spatial and temporal regulated drug release, thereby minimizing side effects and improving therapeutic efficacy of conventional pharmaceuticals. Iron oxide nanoparticles (NPs), specifically Fe304 nanoparticles, possess many appropriate qualities that make them a viable choice for drug delivery.Type: ApplicationFiled: February 7, 2014Publication date: December 31, 2015Applicant: University of Louisville Research Foundation, Inc.Inventors: Ralph J. KNIPP, Michael H. NANTZ
-
Patent number: 8758727Abstract: A contrast marker for indicating a presence of a target cell in an environment comprises a fluorophore, an NMP, and a short spacer and a long spacer linking the fluorophore to the NMP. The short spacer holds the fluorophore at a quenching distance from the NMP and the long spacer holds the fluorophore at a fluorescence enhancing distance from the NMP. The short spacer is configured to be cleaved by a molecule characterizing the target cells.Type: GrantFiled: March 31, 2009Date of Patent: June 24, 2014Assignee: University of Louisville Research Foundation, Inc.Inventors: Kyung A. Kang, Michael H. Nantz
-
Patent number: 8546322Abstract: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the compositions for treating cancer and for delivering an amiloride conjugate into cancer cells in a subject in need thereof.Type: GrantFiled: August 1, 2008Date of Patent: October 1, 2013Assignee: The Regents of the University of CaliforniaInventors: Fredric A. Gorin, Michael H. Nantz
-
Publication number: 20120302516Abstract: The invention provides magnetic nanoparticles comprising a core, wherein the nanoparticles comprise at least one therapeutic agent linked to the core via a hydrazone linkage or via an oxime ether linkage, methods for making said nanoparticles, and methods for using said nanoparticles.Type: ApplicationFiled: October 19, 2010Publication date: November 29, 2012Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Michael H. Nantz, Souvik Biswas
-
Publication number: 20120108494Abstract: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the compositions for treating cancer and for delivering an amiloride conjugate into cancer cells in a subject in need thereof.Type: ApplicationFiled: August 1, 2008Publication date: May 3, 2012Applicant: The Regents of the University of CaliforniaInventors: Fredric A. Gorin, Michael H. Nantz
-
Publication number: 20110195907Abstract: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the treatment of a central nervous system disease or disorder or for the prevention or reduction of ischemia-reperfusion injury using the amiloride conjugates of the present invention.Type: ApplicationFiled: January 3, 2011Publication date: August 11, 2011Applicant: The Regents of the University of California Office of Technology TransferInventors: Fredric A. Gorin, Michael H. Nantz
-
Publication number: 20110104070Abstract: A contrast marker for indicating a presence of a target cell in an environment comprises a fluorophore, an NMP, and a short spacer and a long spacer linking the fluorophore to the NMP. The short spacer holds the fluorophore at a quenching distance from the NMP and the long spacer holds the fluorophore at a fluorescence enhancing distance from the NMP. The short spacer is configured to be cleaved by a molecule characterizing the target cells.Type: ApplicationFiled: March 31, 2009Publication date: May 5, 2011Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Kyung A. Kang, Michael H. Nantz
-
Patent number: 7863415Abstract: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the treatment of a central nervous system disease or disorder or for the prevention or reduction of ischemia-reperfusion injury using the amiloride conjugates of the present invention.Type: GrantFiled: January 21, 2005Date of Patent: January 4, 2011Assignee: The Regents of the University of CaliforniaInventors: Fredric A. Gorin, Michael H. Nantz
-
Publication number: 20080125382Abstract: The present invention relates to compositions and methods for preventing oxidative injury to a cell. The compositions comprise a lipid formulation and a recombinant nucleic acid encoding an extracellular superoxide dismutase (EC-SOD), which upon transfection of a target cell is expressed by the cell and acts as an enzymatic antioxidant. The invention also provides for an isolated organ treated with the claimed composition or method.Type: ApplicationFiled: January 20, 2005Publication date: May 29, 2008Applicant: Regents of the University of CaliforniaInventors: Jian Wu, Michael H. Nantz
-
Publication number: 20040092473Abstract: The present invention describes methods for introducing nucleic acids into a target cell using a transition metal enhancer. A mixture containing nucleic acid and a transition metal enhancer is exposed to cells. The nucleic acid is taken up into the interior of the cell with the aid of the transition metal enhancer. Since nucleic acids can encode a gene, the method can be used to replace a missing or defective gene in the cell. The method can also be used to deliver exogenous nucleic acids operatively coding for proteins that are secreted or released from target cells, thus resulting in a desired biological effect outside the cell. Alternatively, the methods of the present invention can be used to deliver exogenous nucleic acids into a target cell that are capable of regulating the expression of a predetermined endogenous gene.Type: ApplicationFiled: July 9, 2003Publication date: May 13, 2004Applicant: Genteric, Inc.Inventors: Michael J. Bennett, Stephan S. Rothman, Michael H. Nantz
-
Publication number: 20040077888Abstract: The present invention provides cationic lipids and methods that facilitate nucleic acid delivery and which also yield biologically benign metabolites following transfection. The compounds are lipidic polyamines that use a pentaerythritol scaffold to link different hydrophobic and DNA-binding domains.Type: ApplicationFiled: May 30, 2003Publication date: April 22, 2004Applicants: The Regents of the University of California, Genteric, Inc.Inventors: Edmund J. Niedzinski, Michael H. Nantz, Michael Bennett, Mike E. Lizarzaburu
-
Patent number: 6624149Abstract: The present invention describes methods for introducing nucleic acids into a target cell using a transition metal enhancer. A mixture containing nucleic acid and a transition metal enhancer is exposed to cells. The nucleic acid is taken up into the interior of the cell with the aid of the transition metal enhancer. Since nucleic acids can encode a gene, the method can be used to replace a missing or defective gene in the cell. The method can also be used to deliver exogenous nucleic acids operatively coding for proteins that are secreted or released from target cells, thus resulting in a desired biological effect outside the cell. Alternatively, the methods of the present invention can be used to deliver exogenous nucleic acids into a target cell that are capable of regulating the expression of a predetermined endogenous gene.Type: GrantFiled: January 18, 2001Date of Patent: September 23, 2003Assignee: Genteric, Inc.Inventors: Michael J. Bennett, Stephan S. Rothman, Michael H. Nantz
-
Patent number: 6372722Abstract: The present invention describes methods for introducing nucleic acids into a target cell using a transition metal enhancer. A mixture containing nucleic acid and a transition metal enhancer is exposed to cells. The nucleic acid is taken up into the interior of the cell with the aid of the transition metal enhancer. Since nucleic acids can encode a gene, the method can be used to replace a missing or defective gene in the cell. The method can also be used to deliver exogenous nucleic acids operatively coding for proteins that are secreted or released from target cells, thus resulting in a desired biological effect outside the cell. Alternatively, the methods of the present invention can be used to deliver exogenous nucleic acids into a target cell that are capable of regulating the expression of a predetermined endogenous gene.Type: GrantFiled: January 19, 2000Date of Patent: April 16, 2002Assignee: Genteric, Inc.Inventors: Michael J. Bennett, Stephan S. Rothman, Michael H. Nantz